Northeast Pharmaceutical Gets Nod to Market Antiobiotic in Europe

MT Newswires Live

Jun 05

China's Northeast Pharmaceutical Group (SHE:000597) is now allowed to sell fosfomycin trometamol in Europe after obtaining a Certificate of Suitability from the European Directorate for the Quality of Medicines and HealthCare, according to a Shenzhen bourse on Thursday.

The drug is an antibiotic used to treat infections caused by susceptible pathogens, including respiratory tract infections, lower urinary tract infections, and skin and soft tissue infections, the pharmaceutical company said.

The company's shares closed over 1% lower.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2541047603"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541047603\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541047603?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541047603","market":"sh","top_or_hot":-1,"title":"Northeast Pharmaceutical Gets Nod to Market Antiobiotic in Europe","media":"MT Newswires Live","content":"<html><body><p> China's Northeast Pharmaceutical Group (SHE:000597) is now allowed to sell fosfomycin trometamol in Europe after obtaining a Certificate of Suitability from the European Directorate for the Quality of Medicines and HealthCare, according to a Shenzhen bourse on Thursday.</p><p>The drug is an antibiotic used to treat infections caused by susceptible pathogens, including respiratory tract infections, lower urinary tract infections, and skin and soft tissue infections, the pharmaceutical company said.</p><p>The company's shares closed over 1% lower.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Northeast Pharmaceutical Gets Nod to Market Antiobiotic in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNortheast Pharmaceutical Gets Nod to Market Antiobiotic in Europe\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-05 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's Northeast Pharmaceutical Group (SHE:000597) is now allowed to sell fosfomycin trometamol in Europe after obtaining a Certificate of Suitability from the European Directorate for the Quality of Medicines and HealthCare, according to a Shenzhen bourse on Thursday.</p><p>The drug is an antibiotic used to treat infections caused by susceptible pathogens, including respiratory tract infections, lower urinary tract infections, and skin and soft tissue infections, the pharmaceutical company said.</p><p>The company's shares closed over 1% lower.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2541047603","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541047603","pubTimestamp":1749113109,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's Northeast Pharmaceutical Group  is now allowed to sell fosfomycin trometamol in Europe after obtaining a Certificate of Suitability from the European Directorate for the Quality of Medicines and HealthCare, according to a Shenzhen bourse on Thursday.The drug is an antibiotic used to treat infections caused by susceptible pathogens, including respiratory tract infections, lower urinary tract infections, and skin and soft tissue infections, the pharmaceutical company said.The company's shares closed over 1% lower.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","NBN":"东北银行","000597":"东北制药","BK0191":"维生素","BK4211":"区域性银行"},"translate_title":"东北制药获准在欧洲销售抗生素","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBN":1,"000597":0.9},"content_text":"China's Northeast Pharmaceutical Group (SHE:000597) is now allowed to sell fosfomycin trometamol in Europe after obtaining a Certificate of Suitability from the European Directorate for the Quality of Medicines and HealthCare, according to a Shenzhen bourse on Thursday.The drug is an antibiotic used to treat infections caused by susceptible pathogens, including respiratory tract infections, lower urinary tract infections, and skin and soft tissue infections, the pharmaceutical company said.The company's shares closed over 1% lower.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}